Uni-Bio Science Group Limited's latest marketcap:
As of 07/23/2025, Uni-Bio Science Group Limited's market capitalization has reached $95.85 M. According to our data, Uni-Bio Science Group Limited is the 25177th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 95.85 M |
| Revenue (ttm) | 70.44 M |
| Net Income (ttm) | 10.54 M |
| Shares Out | 5.97 B |
| EPS (ttm) | 0 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 05/28/2025 |
| Earnings Date | 08/29/2025 |
Uni-Bio Science Group Limited's yearly market capitalization.
| Date | Market Cap(HK$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/23/2025 | HK$752.37 M | $95.85 M | 100% | 25177 |
| 12/31/2024 | HK$358.27 M | $46.1 M | -20.75% | 28547 |
| 12/29/2023 | HK$452.07 M | $57.87 M | -1.35% | 26800 |
| 12/30/2022 | HK$458.26 M | $58.66 M | -14.08% | 25804 |
| 12/31/2021 | HK$533.38 M | $68.39 M | -27.43% | 25597 |
| 12/31/2020 | HK$734.97 M | $94.77 M | -26.98% | 20929 |
| 12/31/2019 | HK$1.01 B | $129.14 M | 82.99% | 16821 |
| 12/31/2018 | HK$550.02 M | $70.22 M | -40.52% | 19139 |
| 12/29/2017 | HK$924.75 M | $118.33 M | 17.65% | 17113 |
| 12/30/2016 | HK$786.04 M | $101.34 M | -13.03% | 15898 |
Company Profile
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of biological and chemical pharmaceutical products. The company primarily serves the healthcare market in the People’s Republic of China.
Business Segments
- Chemical Pharmaceutical Products
- Biological Pharmaceutical Products
- Pipeline Products
Key Products
- GeneTime – A prescription biological drug for wound healing.
- GeneSoft – A therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing.
- Pinup – A voriconazole tablet for severe fungal infections.
- Boshutai – A small molecule drug for diabetes treatment.
Pipeline Developments
- rExendin-4 (Uni-E4) – For Type 2 diabetes.
- rhPTH 1-34 (Uni-PTH) – For osteoporosis treatment in postmenopausal women.
- Uni-GLP – A GLP-1 agent for Type 2 diabetes.
Additional Operations
The company also distributes hydrogel wound dressings for post-skin injury and minimally invasive surgery wound healing.
Company Background
Founded in 2001, Uni-Bio Science Group Limited is headquartered in Sha Tin, Hong Kong.
Frequently Asked Questions
-
What is Uni-Bio Science Group Limited's (HKG-0690) current market cap?As of 07/23/2025, Uni-Bio Science Group Limited (including the parent company, if applicable) has an estimated market capitalization of $95.85 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Uni-Bio Science Group Limited (HKG-0690) rank globally by market cap?Uni-Bio Science Group Limited global market capitalization ranking is approximately 25177 as of 07/23/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.